adaptor related protein complex 1 subunit gamma 1Genealiases: ADTG · CLAPG1 · USRISD
Q-omics provides the consensus-scored AP1G1 profile across patient tissues and cancer cell-line models. AP1G1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AP1G1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, AP1G1 protein abundance shows 20,805 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, BLCA, and PDAC as cancer lineages where AP1G1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AP1G1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AP1G1 survival associations across molecular data types. AP1G1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AP1G1 RNA expression–survival associations across cancer types. High AP1G1 expression shows unfavorable associations in BLCA, LUSC, ACC and PAAD, but favorable associations in KIRC and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AP1G1 RNA expression.
This table summarizes AP1G1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AP1G1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AP1G1 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in BLCA, HNSC and CHOL. The BLCA box plot shows higher AP1G1 RNA expression in tumor versus normal tissue (log2 FC = +0.690, t-test p < 0.001).
This table shows molecular features associated with AP1G1 in patient tissues and cancer cell lines. In patient samples, AP1G1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, AP1G1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
